SCHEMBL5545866

SCHEMBL5545866

COCCNC(=O)c1c(O)c2ncc(Cc3ccc(F)cc3)cc2n(Cc2ccc(NC(C)=O)cc2)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
TP53 P04637 1/20 0.42
ALDH1A1 P00352 4/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 1/20 0.41
CNR2 P34972 6/20 0.40
ERCC5 P28715 1/20 0.39
CNR1 P21554 1/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
EGLN1 Q9GZT9 1/20 0.37
P2RX3 P56373 1/20 0.37
HSD17B10 Q99714 1/20 0.37
GRIN1 Q05586 1/20 0.36
GRIN2B Q13224 1/20 0.36
GAA P10253 1/20 0.36
HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540865 0.92 MAPT (0.43) MAPTTP53ALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL5545466 0.91 KCNH2 (0.45) MAPTTP53ALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL15163560 0.90 TP53 (0.42) MAPTTP53ALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL5545301 0.89 KDM4E (0.47) MAPTTP53ALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL5546845 0.88 L3MBTL1 (0.41) MAPTALDH1A1L3MBTL1SMN1; SMN2MEN1
SCHEMBL5546797 0.88 EGLN1 (0.42) ALDH1A1L3MBTL1SMN1; SMN2MEN1KMT2A
SCHEMBL5545366 0.87 L3MBTL1 (0.43) MAPTALDH1A1L3MBTL1SMN1; SMN2MEN1
SCHEMBL5538405 0.86 CNR2 (0.46) MAPTTP53ALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL5548090 0.85 L3MBTL1 (0.42) MAPTALDH1A1L3MBTL1SMN1; SMN2MEN1
SCHEMBL5545596 0.85 L3MBTL1 (0.42) MAPTALDH1A1L3MBTL1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 MAPT 2173/4885TP53 4123/4885ALDH1A1 3812/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 MAPT 949/4885TP53 2849/4885ALDH1A1 3073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.